Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings turns positive
Q3 FY2026 retained earnings was $513.44M, compared with -$496.16M a year earlier.
Context
- Retained earnings amounted to 28.8% of total assets at the end of Q3 FY2026, down 56.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +203.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (546.37M) USD
- Year-over-year change
- -44.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (546.37M) | -44.3% |
| FY2024 | 2024-12-31 | (378.58M) | -54.7% |
| FY2023 | 2023-12-31 | (244.76M) | -69.3% |
| FY2022 | 2022-12-31 | (144.6M) | -87.9% |
| FY2021 | 2021-12-31 | (76.96M) | — |
Retained Earnings vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's Sep 2026 retained earnings of $513.44M is the highest of the 10 companies compared; the peer median is -$547.72M.
- Its year-over-year change of +203.5% is the highest of 10, against a peer median of -44.2%.
- Retained earnings amounts to 28.8% of total assets for EWTX, versus a peer median of 143.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $513.44M | +203.5% | — | 28.8% | |
| Mar 2026 | -$312.81M | -113.2% | — | 93.2% | |
| Mar 2026 | -$338.82M | -51.1% | — | 103.8% | |
| Mar 2026 | -$378.88M | -25.6% | — | 242.4% | |
| Mar 2026 | -$464.44M | -55.6% | — | 222.7% | |
| Mar 2026 | -$547.72M | -44.9% | — | 123.6% | |
| Mar 2026 | -$1.01B | -23.3% | — | 239.9% | |
| Jun 2026 | -$1.7B | -44.2% | — | 170.6% | |
| Jun 2026 | -$2.88B | -1.3% | — | 88.7% | |
| Mar 2026 | -$4.55B | +2.4% | — | 143.0% | |
| Peer median (excluding EWTX) | -$547.72M | -44.2% | — | 143.0% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.57M | 21.99M | 86.1M | 41.67M | 61.15M |
| Short-term Investments | 265.22M | 329.95M | 232.3M | 428.5M | 468.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 8.6M | 5.31M | 13.28M |
| Total Current Assets | 283.77M | 357M | 327M | 475.48M | 543.39M |
| Property, Plant & Equipment (Net) | 912K | 9.85M | 12.69M | 11.07M | 9.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 548K | 251K | 348K | 262K | 0 |
| Total Non-current Assets | 1.46M | 10.1M | 13.04M | 11.33M | 9.22M |
| Total Assets | 285.23M | 367.1M | 340.04M | 486.82M | 552.6M |
| Account Payables | 3.84M | 6.11M | 4.03M | 5.58M | 6.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.8M | 4.03M | 5.7M | 10.06M | 12.43M |
| Total Current Liabilities | 10.52M | 16.59M | 16.77M | 23.86M | 27.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.98M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 329K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 329K | 3.8M | 4.43M | 3.74M | 2.98M |
| Total Liabilities | 10.85M | 20.39M | 21.21M | 27.6M | 30.35M |
| Common Stock | 5K | 6K | 7K | 9K | 10K |
| Retained Earnings | (76.96M) | (144.6M) | (244.76M) | (378.58M) | (546.37M) |
| Accumulated OCI | (514K) | (1.36M) | 99K | 420K | 677K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 274.38M | 346.72M | 318.83M | 459.22M | 522.26M |
| Total Debt | 0 | 4.41M | 5.41M | 4.74M | 3.99M |
| Net Debt | (15.57M) | (17.59M) | (80.68M) | (36.93M) | (57.16M) |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.